Related Experiment Video
Updated: Aug 15, 2026

Fetal Mouse Cardiovascular Imaging Using a High-frequency Ultrasound (30/45MHZ) System
Published on: May 5, 2018
Chronic hypertension in pregnancy
Insights
Managing chronic hypertension in pregnancy requires more than just blood pressure control. Key factors include accurate dating, addressing medical issues, fetal monitoring, and timely delivery for optimal outcomes.
Area of Science:
- Obstetrics and Gynecology
- Cardiology
- Perinatology
Background:
- Chronic hypertension affects 169 pregnancies in 156 women.
- Antihypertensive medication initiated if diastolic blood pressure > 90 mmHg.
- Associated medical conditions identified as significant factors.
Purpose of the Study:
- To investigate the course and outcomes of pregnancies complicated by chronic hypertension.
- To identify high-risk indicators and assess the impact of antihypertensive therapy.
Main Methods:
- Retrospective study of 169 pregnancies in women with chronic hypertension.
- Monitoring of blood pressure, associated medical conditions, and pregnancy outcomes.
- Analysis of perinatal mortality, superimposed preeclampsia, and fetal growth retardation.
Main Results:
- High-risk indicators: left ventricular hypertrophy, serum creatinine > 1.0 mg%, early diastolic pressure > 100 mmHg.
- Perinatal mortality: 28.4/1000. Superimposed preeclampsia affected one-third of patients.
- Fetal growth retardation occurred in 15%, with higher incidence (20% vs 5%) in those treated with antihypertensives, particularly methyldopa.
Conclusions:
- Controlling blood pressure is crucial but insufficient for managing chronic hypertension in pregnancy.
- Accurate dating, managing comorbidities, antenatal fetal assessment (ultrasound, heart rate monitoring), and timely delivery are vital.
- Perinatal outcomes were similar to studies withholding antihypertensive therapy, suggesting a multifactorial approach is essential.
Abstract:
The course and outcome of 169 pregnancies in 156 women with chronic hypertension were studied. Antihypertensive medications were given if the diastolic blood pressure exceeded 90 mmHg. A number of major associated medical problems were found. Left ventricular hypertrophy, a serum creatinine greater than 1.0 mg%, and a diastolic pressure greater than 100 mmHg at less than 20 weeks' gestation were high-risk indicators. The overall perinatal mortality was 28.4 of 1000 (versus hospital of 25.6 of 1000). Despite antihypertensive therapy, one-third of the patients developed superimposed preeclampsia. The poorest outcome occurred in patients with superimposed preeclampsia necessitating delivery at 27 to 34 weeks' gestation (perinatal mortality = 238 of 1000). Antepartum fetal heart rate testing was abnormal in 10% of the patients with intrauterine growth retardation occurring in 15%. The incidence of fetal growth retardation was fourfold higher (20 versus 5%) in patients treated with antihypertensive drugs, particularly methyldopa as a single agent. However, this may have been related more to the study design than to a detrimental effect of the drug. The perinatal outcome in this study is similar to the outcome of studies in which antihypertensive therapy was withheld. This indicates that controlling the blood pressure is merely one aspect of the management of chronic hypertension in pregnancy. Accurate dating, attention to associated medical problems, antenatal fetal assessment by ultrasound and heart rate monitoring, and carefully timed delivery are additional important factors.
Related Concept Videos
Hormonal Regulation
Hypertension and Regulation of Blood Pressure
Hypertension I: Introduction
Hypertension II: Pathophysiology
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension V: Nursing Management

